Pure Global AI
ISRCTN60839016

Artificial intelligence in mammography study

Clinical validation of an artificial intelligence system to improve the quality, efficiency and experience of breast cancer screening
Imperial College LondonISRCTN Registryother
VerifiedISRCTN Registry
Study focus
Disease/Condition
Malignant neoplasm of breast
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Imperial College London
Funder
National Institute for Health Research
Location
United Kingdom
Timeline & enrollment
Phase
N/A
Start date
May 20, 2021
End date
May 21, 2024
Enrollment
68000 participants
Summary

A novel AI system for breast cancer screening demonstrates the appropriate accuracy, safety, acceptability, and cost-effectiveness required for use as an independent reader within the NHS breast screening programme.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastMalignant neoplasm: Breast, unspecifiedMalignant neoplasm: Central portion of breastPersonal history of malignant neoplasm of breast
Data source
Registry
ISRCTN Registry
Trial ID
ISRCTN60839016
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for ISRCTN60839016 through Pure Global AI's free database. This phase not specified trial is sponsored by Imperial College London and is currently status unknown. The study focuses on Malignant neoplasm of breast. Target enrollment is 68000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ISRCTN Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.